ReviewMissouri medicine
The Role of Artificial Intelligence in Acute Ischemic Stroke Care: A Narrative Review.
Review in Missouri medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute ischemic stroke remains a leading cause of death and disability; despite time-dependent reperfusion therapies, delays in recognition, imaging interpretation, triage, and specialist access still limit timely treatment. This narrative review outlines how artificial intelligence (AI) may reduce bottlenecks across the stroke pathway. Prehospital tools include dispatcher decision support, consumer wearables, mobile assessment apps, and portable diagnostics may improve early detection and destination selection. In-hospital, AI increasingly assists neuroimaging and workflow, including intracranial hemorrhage detection, automated ASPECTS scoring, large vessel occlusion identification, and perfusion-based estimation of tissue salvageability, often shortening notification and process times. We also discuss AI-enabled risk stratification, systems-of-care coordination, and emerging uses of generative AI for documentation and communication. Key limitations include domain shift, incomplete external validation, bias and equity risks, limited explainability, alert fatigue, integration challenges, and evolving regulatory accountability. Future priorities include multimodal models, prospective implementation-focused trials, and deployment-ready solutions for diverse real-world settings.
Indexed as
Identifiers
42281641PMC13252889What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.